Clostridioides difficile infection in immunocompromised hospitalized patients is associated with a high recurrence rate

Abstract

IMC patients with CDI have an increased risk of 90 days rCDI. Vancomycin treatment for CDI endangers recurrence in IMC patients. Further research should explore other therapies for IMC patients with CDI with alternative agents such as Fidaxomicin and Bezlotoxumab.